Roche reports interim Tam-Peli phase III survival benefit in relapsed SCLC

The source explicitly reports a new interim randomized phase III TAISHAN-302 readout on 13 September 2026, with Tam-Peli meeting its primary overall-survival endpoint and showing a substantial mortality reduction versus topotecan. This is a forward-looking clinical development with potential regulatory, commercial, and competitive implications, not a market-performance or commentary item. The description is kept focused on the clinical-trial result; the separately stated Chinese NDA filing acceptance is treated as a related but distinct regulatory milestone. The date is explicit, but the exact time is not, so 00:00 UTC is used as a date-level estimate. Roche is directly exposed through its disclosed ex-China development, manufacturing, and commercialization rights; the approved competitor stakeholders have therapies explicitly identified in the provided context as competing in relapsed SCLC, while indirect CDMOs and less-overlapping lung-cancer programs are excluded.